MedTrace Logo

A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer

NCT04138992 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2020-06-30

No results posted yet for this study

Summary

To verify the clinical efficacy and safety of bevacizumab in treating local advanced cervical cancer, present study was designed to investigate the clinical results of bevacizumab combined with concurrent chemoradiotherapy (CCRT) in local advanced cervical cancer

Conditions

  • Disease Free Survival

Interventions

DRUG

bevacizumab

bevacizumab will be used during neoadjuvant and concurrent chemoradiotherapy

DRUG

DDP

DDP will be used during neoadjuvant and concurrent chemoradiotherapy

DRUG

Docetaxel

used in neoadjuvant chemotherapy

RADIATION

radiotherapy

standard treatment includes pelvic external beam radiation and brachytherapy

Sponsors & Collaborators

  • Air Force Military Medical University, China

    lead OTHER

Principal Investigators

  • mei shi, M.D. · Xijing Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-05-31
Completion
2022-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04138992 on ClinicalTrials.gov